Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guardian Pharmacy ServicesGRDN +0.89%42 Debt-to-EBITDA is 0.38 as of Mar. 2026, which is 64% below its 10-year median of 1.06. GuruFocus rates GRDN with a GF Score™ of 42/100. The stock has 4 warning signs investors should review. Among 477 Healthcare Providers & Services companies, Guardian Pharmacy Services ranks better than 84.91% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Guardian Pharmacy Services's Debt-to-EBITDA or its related term are showing as below:
GRDN'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.69 Med: 1.06 Max: 1.2
Current: 0.36
During the past 8 years, the highest Debt-to-EBITDA Ratio of Guardian Pharmacy Services was 1.20. The lowest was -0.69. And the median was 1.06.
GRDN's Debt-to-EBITDA is ranked better than 84.91% of 477
companies
in the Healthcare Providers & Services industry
Industry Median: 2.22
vs GRDN: 0.36
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Guardian Pharmacy Services Debt-to-EBITDA Related Terms
Guardian Pharmacy Services Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GRDN vs ACHC, ASTH, NHC: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Guardian Pharmacy Services's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardian Pharmacy Services Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Guardian Pharmacy Services's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Guardian Pharmacy Services's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Guardian Pharmacy Services (GRDN) has a Debt-to-EBITDA of 0.38 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Guardian Pharmacy Services. This is 64% below median its historical median of 1.06. According to the industry distribution chart, Guardian Pharmacy Services ranks #72 out of 477 companies in the Healthcare Providers & Services industry, placing it in the top 15.1%.
Is Guardian Pharmacy Services' Debt-to-EBITDA too high?
Guardian Pharmacy Services' current Debt-to-EBITDA of 0.38 is 64% below median its 10-year median of 1.06. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.22. Guardian Pharmacy Services' value of 0.38 is 82.9% below this industry median. Based on the distribution chart, Guardian Pharmacy Services ranks #72 out of 477 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Guardian Pharmacy Services has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Guardian Pharmacy Services' Debt-to-EBITDA compare to ACHC and ASTH?
According to the Healthcare Providers & Services industry distribution chart, Guardian Pharmacy Services ranks #72 out of 477 companies for Debt-to-EBITDA. This places Guardian Pharmacy Services in the top 15% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.22. Guardian Pharmacy Services' value of 0.38 is 82.9% below this benchmark. While the company's 10-year median is 1.06 vs. the industry median of 2.22, Guardian Pharmacy Services has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.22, based on 477 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guardian Pharmacy Services's current Debt-to-EBITDA of 0.38 is 82.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Guardian Pharmacy Services. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guardian Pharmacy Services's current Debt-to-EBITDA is 0.38, which is 64% below median its own 10-year median of 1.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guardian Pharmacy Services stock overvalued right now?
Guardian Pharmacy Services (GRDN) has a current Debt-to-EBITDA of 0.38. The current Debt-to-EBITDA is 0.38, which is 64% below median its 10-year median of 1.06 and 82.9% below the Healthcare Providers & Services industry median of 2.22. Guardian Pharmacy Services' overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Guardian Pharmacy Services (GRDN), the current Debt-to-EBITDA is 0.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Guardian Pharmacy Services Inc is a pharmacy services company providing technology-enabled services to help residents of long-term health care facilities (LTCFs) adhere to appropriate drug regimens, reducing the cost of care and improving clinical outcomes. The Company provides high-touch clinical, drug dispensing, and administration services tailored to residents in assisted living facilities, behavioral health facilities, and group homes, while also serving residents in all types of LTCFs. It partners with residents, LTCFs, and health plan payors to help reduce errors in drug administration, manage drug regimens, and improve adherence. The Company derives its revenue mainly from the sale of pharmaceutical and medical products.
42GF Score
Get the complete analysis for GRDN
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRDN has been successfully added to your 
